Gemcitabine combination chemotherapy of ovarian cancer
- 1 August 2003
- journal article
- review article
- Published by Elsevier in Gynecologic Oncology
- Vol. 90 (2) , S16-S20
- https://doi.org/10.1016/s0090-8258(03)00339-1
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Gemcitabine Reverses Cisplatin Resistance: Demonstration of Activity in Platinum- and Multidrug-Resistant Ovarian and Peritoneal CarcinomaGynecologic Oncology, 2003
- A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapyAnnals of Oncology, 2002
- Developmental chemotherapy in advanced ovarian cancer: Incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182)Seminars in Oncology, 2002
- Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer – a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study GroupAnnals of Oncology, 2001
- Topotecan and Gemcitabine in Platinum/Paclitaxel-Resistant Ovarian CancerOncology, 2000
- Phase II study of gemcitabine in ovarian cancerAnnals of Oncology, 1999
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerAnnals of Oncology, 1996
- Phase II study of gemcitabine in previously platinum-treated ovarian cancer patientsAnti-Cancer Drugs, 1995